Regenerative therapies for rare GI diseases.
Triada Biosciences is an early-stage biotechnology company based in Mill Valley, California. We are operating in stealth and welcome conversations with prospective partners, collaborators and investors.
Get in touch- Stage
- Early stage
- Headquarters
- Mill Valley, California
- Status
- In stealth
Our approach
Three strands run through our work: deep scientific insight, disciplined translation and close partnership.
We partner with patients, doctors, and scientists to efficiently develop life-changing therapies.
Leadership
Andrew Grimm, MD, PhD
Founder & Chief Executive Officer
Andrew is a physician-scientist, pediatric gastroenterologist, and experienced drug developer. At Shire and Takeda, he led development of Gattex, a GLP-2 analog, for the treatment of intestinal failure due to short bowel syndrome. As the head of clinical development for inborn errors of metabolism at Ultragenyx, he led development of Genglycos, the recently approved AAV gene therapy for the treatment of glycogen storage disease type 1a, as well as global expansion of Evkeeza for the treatment of homozygous familial hypercholesterolemia, and Dojolvi for the treatment of long-chain fatty acid oxidation disorders. He trained at MIT, Washington University, Boston Children’s Hospital, and UCSF. He is based in Mill Valley, CA.